William Blair analyst Matt Phipps has maintained their bullish stance on TENX stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matt Phipps has given his Buy rating due to a combination of factors surrounding the promising developments in Tenax Therapeutics’ clinical trials. Specifically, the Phase III LEVEL trial for oral levosimendan in treating pulmonary hypertension with preserved ejection fraction (PH-HFpEF) remains highly powered at over 90%, following a blinded sample size re-estimation. This adjustment, which confirmed lower variability in trial data than expected, reinforces the confidence in the trial’s design and statistical robustness.
Moreover, the consistent data from previous studies, including the Phase II HELP trial, and positive feedback from investigators involved in the program further highlight the therapy’s potential. With the trial results on track for release in the second half of 2026 and the initiation of the second Phase III LEVEL-2 study, Matt Phipps views these advancements as significant catalysts for the company’s stock. Consequently, he maintains an optimistic outlook on Tenax’s progress, reiterating a Buy rating.
In another report released yesterday, Guggenheim also reiterated a Buy rating on the stock with a $25.00 price target.